Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Clinical Trial
. 2014 Feb 5;9(2):e87113.
doi: 10.1371/journal.pone.0087113. eCollection 2014.

Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements

Free PMC article
Clinical Trial

Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements

Jan B Egan et al. PLoS One. .
Free PMC article


Liposarcoma is the most common soft tissue sarcoma, but little is known about the genomic basis of this disease. Given the low cell content of this tumor type, we utilized flow cytometry to isolate the diploid normal and aneuploid tumor populations from a well-differentiated liposarcoma prior to array comparative genomic hybridization and whole genome sequencing. This work revealed massive highly focal amplifications throughout the aneuploid tumor genome including MDM2, a gene that has previously been found to be amplified in well-differentiated liposarcoma. Structural analysis revealed massive rearrangement of chromosome 12 and 11 gene fusions, some of which may be part of double minute chromosomes commonly present in well-differentiated liposarcoma. We identified a hotspot of genomic instability localized to a region of chromosome 12 that includes a highly conserved, putative L1 retrotransposon element, LOC100507498 which resides within a gene cluster (NAV3, SYT1, PAWR) where 6 of the 11 fusion events occurred. Interestingly, a potential gene fusion was also identified in amplified DDR2, which is a potential therapeutic target of kinase inhibitors such as dastinib, that are not routinely used in the treatment of patients with liposarcoma. Furthermore, 7 somatic, damaging single nucleotide variants have also been identified, including D125N in the PTPRQ protein. In conclusion, this work is the first to report the entire genome of a well-differentiated liposarcoma with novel chromosomal rearrangements associated with amplification of therapeutically targetable genes such as MDM2 and DDR2.

Conflict of interest statement

Competing Interests: I have read the journal's policy and have the following conflicts. RF has received a patent for the prognostication of MM based on genetic categorization of the disease. He has received consulting fees from Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millenium and AMGEN. He also has sponsored research from Cylene and Onyx. All other authors have no competing interests to declare. The competing interests statement does not alter our adherence to all the PLOS ONE policies on sharing data and materials.


Figure 1
Figure 1. Circos plot of validated genetic variation in a well-differentiated liposarcoma.
Inner-most circle contains validated structural rearrangements of fusion genes with translocations indicated in purple, and intra-chromosomal rearrangements indicated in orange. The middle ring contains the aCGH plot with copy number loss indicated in green and copy number gain in red; each orange ring corresponds to a log2 value of 1. The outer-most ring indicates validated, damaging single nucleotide variants.
Figure 2
Figure 2. aCGH and Fluorescent in-situ hybridization of DDR2, MDM2, and SYT1.
(A) aCGH dot plots of the chromosomal region of each gene. Tan colored shading indicates regions of significant copy number change. Red dots indicate copy number gain and green dots indicate copy number loss. (B) FISH images of cells probed for the indicated genes with SpectrumOrange probe and the chromosome control indicated with the SpectrumGreen probe.
Figure 3
Figure 3. Depiction of genomic rearrangement hotspot on chromosome 12.
We identified and further characterized a putative transposable element (LOC100507498) located on the (-) strand, within the PAWR-SYT1-NAV3 gene cluster (3A). The LOC100507498 and closely related sequences were characterized by comparing both nucleotide (3B,top) and translated (3B,bottom) sequences to known families of repetitive elements (Methods). Highly conserved sequence domains/motifs are color coded by known families of repetitive elements (Legend). Overall, these sequences exhibited the highest similarity to the L1 retrotransposon and Alu repeat elements (domain hit counts and similarity score). Sequence alignments of LOC100507498 (*) with known L1 elements , exhibited the highest overall homology to Class 3 L1 elements as described by Pickeral et al. (Table 1, [32]) and in addition to the 5′-GGAG and 3′-AATA signature motifs, LOC100507498 carries several ‘AATGTTTA’ motifs that suggest multiple rounds of L1-mediated transduction . The LOC100507498 locus resides within a genomic region that is deleted in the Tumor (T) sample, but present in the Normal (N) genome (3C).

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. Fletcher CDM, Unni KK, Mertens F (Eds.) (2002) Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press. 415 p.
    1. Crago AM, Singer S (2011) Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 23: 373–378. - PMC - PubMed
    1. Hameed M (2007) Pathology and genetics of adipocytic tumors. Cytogenet Genome Res 118: 138–147. - PubMed
    1. Conyers R, Young S, Thomas DM (2011) Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011: 483154. - PMC - PubMed
    1. Boland MV, Quigley HA (2011) Evaluation of a combined index of optic nerve structure and function for glaucoma diagnosis. BMC Ophthalmol 11: 6. - PMC - PubMed

Publication types